Related Experiment Videos
Coronary reocclusion after selective administration of streptokinase
Insights
Intracoronary streptokinase achieved reflow in 85% of acute myocardial infarction patients. Long-term success may require anticoagulation or procedures to bypass residual stenosis.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Acute transmural myocardial infarction requires prompt reperfusion.
- Intracoronary streptokinase is a thrombolytic agent used to restore coronary blood flow.
Purpose of the Study:
- To evaluate the efficacy and outcomes of intracoronary streptokinase in patients with acute transmural myocardial infarction.
- To assess factors influencing reflow, reocclusion, and long-term patency.
Main Methods:
- 40 patients with acute transmural myocardial infarction received intracoronary streptokinase.
- Percutaneous angioplasty and bypass surgery were performed in select cases.
- Follow-up included assessment of recurrent ischemia and coronary patency.
Main Results:
- 85% of patients achieved reflow or improved flow with streptokinase.
- Six patients showed no reflow, and six experienced early reocclusion.
- Recurrent ischemia was observed in patients treated with streptokinase alone, unlike those undergoing angioplasty or bypass surgery.
Conclusions:
- Intracoronary streptokinase is effective for initial reperfusion in myocardial infarction.
- Long-term coronary patency may necessitate continued anticoagulation or interventions like angioplasty or bypass surgery to address residual stenosis.
Abstract:
Intracoronary streptokinase was given to 40 patients with acute transmural myocardial infarction. In 34 of the patients (85%), it resulted in reflow or improved flow. Six patients showed no reflow and six reocclusion within 2 hours. No consistent explanation was found for this resistance to therapy. Five other patients developed reocclusion after 6 days to 11 months, when heparin or warfarin anticoagulation had been stopped. Percutaneous angioplasty at the time of streptokinase infusion was performed in seven, with six successes. Bypass surgery was performed after successful streptokinase administration in eight. Follow-up revealed recurrent ischemia in patients successfully treated with streptokinase alone, but not in patients with successful angioplasty or bypass surgery. Long-term coronary patency after thrombolysis may require careful anticoagulation or a procedure that modifies or bypasses the residual stenosis.